Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more


LRG2.1_Puro Citations (2)

Originally described in: Salt-Inducible Kinase inhibition suppresses acute myeloid leukemia progression in vivo.
Tarumoto Y, Lin S, Wang J, Milazzo JP, Xu Y, Lu B, Yang Z, Wei Y, Polyanskaya S, Wunderlich M, Gray NS, Stegmaier K, Vakoc CR Blood. 2019 Nov 1. pii: 422697. doi: 10.1182/blood.2019001576.
PubMed Journal

Articles Citing LRG2.1_Puro

BAP1 enhances Polycomb repression by counteracting widespread H2AK119ub1 deposition and chromatin condensation. Conway E, Rossi F, Fernandez-Perez D, Ponzo E, Ferrari KJ, Zanotti M, Manganaro D, Rodighiero S, Tamburri S, Pasini D. Mol Cell. 2021 Sep 2;81(17):3526-3541.e8. doi: 10.1016/j.molcel.2021.06.020. Epub 2021 Jun 28. PubMed
PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. Patel AJ, Warda S, Maag JLV, Misra R, Miranda-Roman MA, Pachai MR, Lee CJ, Li D, Wang N, Bayshtok G, Fishinevich E, Meng Y, Wong EWP, Yan J, Giff E, Pappalardi MB, McCabe MT, Fletcher JA, Rudin CM, Chandarlapaty S, Scandura JM, Koche RP, Glass JL, Antonescu CR, Zheng D, Chen Y, Chi P. Cancer Discov. 2022 Sep 2;12(9):2120-2139. doi: 10.1158/2159-8290.CD-21-1671. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.